Maintenance Selinexor Shows PFS in TP53 Wild-type Endometrial Cancer
Cancer Network,
Selinexor did not show a clinically meaningful improvement in the general study population.
ENGOT-EN20/GOG-3083/xport-EC-042: A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 wild-type…
Overview of attention for article published in Journal of Clinical Oncology, May 2023
Altmetric Badge
About this Attention Score
-
Good Attention Score compared to outputs of the same age (67th percentile)
-
Average Attention Score compared to outputs of the same age and source
Readers on
- mendeley
- 9 Mendeley